FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2058521000> ?p ?o ?g. }

• W2058521000 abstract "Breast cancer is a multi-stage process which leads to the accumulation of abnormal cells arising from excessive proliferation, lack of apoptosis or a combination of both. Natural compounds such as g-tocotrienol have been shown to selectively inhibit cancer cell growth without harming normal cell viability with little or no adverse side effects. The antiproliferative and apoptotic effects of the tocotrienol isoform, γ-tocotrienol, have been firmly established in various cancer types. However, in vivo studies have provided mixed results, attributed to γ-tocotrienol rapid clearance and low bioavailability. In order to improve anticancer potency and bioavailability in vivo , γ- and Δ-tocotrienol were chemically modified with electrophilic substitution reactions on their chromane ring using Mannich and Lederer-Manasse reactions, resulting in the synthesis of various oxazine derivatives. Several of these oxazine derivatives (compounds 26, 31, 39, 40 and 44) were found to display potent anticancer activity as compared to their parent compounds when tested on +SA mammary cancer cells grown in culture. These in vitro studies were followed up with in vivo studies to determine the anticancer effects of oxazine derivatives on the growth of mammary tumors in mice. Female syngeneic BALB/c mice, 4-6 week old were inoculated with 1×10 6 +SA mammary tumor cells in the left mammary pad. Once tumor size reached 5mm in diameter, animals were divided into different treatment groups and received an intra-tumoral injection injected of 0-120μg/20μl tocotrienol or its derivative every other day for 11 days. Afterwards, mice were sacrificed, tumors removed and placed in -80°C until further analysis. Results from these studies showed that tumor growth rate was significantly reduced in the oxazine derivative treated animals as compared to the vehicle-treated controls. Western blot analysis of tumor samples showed that the growth inhibitory effects of tocotrienol derivatives was also associated with a significant reduction in phosphorylated (activated) Akt and reductions in cell cycle regulatory proteins cyclin D1 and cyclin dependent kinases (CDK2, CDK4 and CDK6). In addition, oxazine derivative treatment was also associated with a large increase in CDK inhibitors p21 and p27, as compared to tumors obtained from the vehicle-treated control mice. Western blot analysis also showed that tumor from oxazine-derivative treated mice displayed a large reduction in NFκB levels and its downstream gene product COX-2. In summary, oxazine derivatives of tocotrienols display more potent anticancer activity both in vitro and in vivo , as compared to their parent compounds and suggest that these tocotrienol derivatives may provide some benefit as novel anticancer therapeutic agents. This work was supported, in part, by First Tec International Ltd. (Hong Kong), Malaysian Palm oil Council and the Louisiana Cancer Foundation. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-03-11." @default.
• W2058521000 created "2016-06-24" @default.
• W2058521000 creator A5019892485 @default.
• W2058521000 creator A5021970454 @default.
• W2058521000 creator A5041668978 @default.
• W2058521000 creator A5048951136 @default.
• W2058521000 creator A5059085312 @default.
• W2058521000 creator A5062406222 @default.
• W2058521000 creator A5085928493 @default.
• W2058521000 date "2013-12-15" @default.
• W2058521000 modified "2023-10-10" @default.
• W2058521000 title "Abstract P3-03-11: Oxazine derivatives of g- and D- tocotrienols display potent anticancer effects in vivo" @default.
• W2058521000 doi "https://doi.org/10.1158/0008-5472.sabcs13-p3-03-11" @default.
• W2058521000 hasPublicationYear "2013" @default.
• W2058521000 type Work @default.
• W2058521000 sameAs 2058521000 @default.
• W2058521000 citedByCount "1" @default.
• W2058521000 crossrefType "proceedings-article" @default.
• W2058521000 hasAuthorship W2058521000A5019892485 @default.
• W2058521000 hasAuthorship W2058521000A5021970454 @default.
• W2058521000 hasAuthorship W2058521000A5041668978 @default.
• W2058521000 hasAuthorship W2058521000A5048951136 @default.
• W2058521000 hasAuthorship W2058521000A5059085312 @default.
• W2058521000 hasAuthorship W2058521000A5062406222 @default.
• W2058521000 hasAuthorship W2058521000A5085928493 @default.
• W2058521000 hasConcept C121608353 @default.
• W2058521000 hasConcept C126322002 @default.
• W2058521000 hasConcept C150903083 @default.
• W2058521000 hasConcept C181389837 @default.
• W2058521000 hasConcept C185592680 @default.
• W2058521000 hasConcept C190283241 @default.
• W2058521000 hasConcept C202751555 @default.
• W2058521000 hasConcept C207001950 @default.
• W2058521000 hasConcept C2776187077 @default.
• W2058521000 hasConcept C2777551382 @default.
• W2058521000 hasConcept C2778004101 @default.
• W2058521000 hasConcept C2778310972 @default.
• W2058521000 hasConcept C2781449162 @default.
• W2058521000 hasConcept C530470458 @default.
• W2058521000 hasConcept C55493867 @default.
• W2058521000 hasConcept C71924100 @default.
• W2058521000 hasConcept C86803240 @default.
• W2058521000 hasConcept C96232424 @default.
• W2058521000 hasConcept C98274493 @default.
• W2058521000 hasConceptScore W2058521000C121608353 @default.
• W2058521000 hasConceptScore W2058521000C126322002 @default.
• W2058521000 hasConceptScore W2058521000C150903083 @default.
• W2058521000 hasConceptScore W2058521000C181389837 @default.
• W2058521000 hasConceptScore W2058521000C185592680 @default.
• W2058521000 hasConceptScore W2058521000C190283241 @default.
• W2058521000 hasConceptScore W2058521000C202751555 @default.
• W2058521000 hasConceptScore W2058521000C207001950 @default.
• W2058521000 hasConceptScore W2058521000C2776187077 @default.
• W2058521000 hasConceptScore W2058521000C2777551382 @default.
• W2058521000 hasConceptScore W2058521000C2778004101 @default.
• W2058521000 hasConceptScore W2058521000C2778310972 @default.
• W2058521000 hasConceptScore W2058521000C2781449162 @default.
• W2058521000 hasConceptScore W2058521000C530470458 @default.
• W2058521000 hasConceptScore W2058521000C55493867 @default.
• W2058521000 hasConceptScore W2058521000C71924100 @default.
• W2058521000 hasConceptScore W2058521000C86803240 @default.
• W2058521000 hasConceptScore W2058521000C96232424 @default.
• W2058521000 hasConceptScore W2058521000C98274493 @default.
• W2058521000 hasLocation W20585210001 @default.
• W2058521000 hasOpenAccess W2058521000 @default.
• W2058521000 hasPrimaryLocation W20585210001 @default.
• W2058521000 hasRelatedWork W1486380606 @default.
• W2058521000 hasRelatedWork W1582428559 @default.
• W2058521000 hasRelatedWork W1986370576 @default.
• W2058521000 hasRelatedWork W1997346419 @default.
• W2058521000 hasRelatedWork W2002293147 @default.
• W2058521000 hasRelatedWork W2039718645 @default.
• W2058521000 hasRelatedWork W2052064785 @default.
• W2058521000 hasRelatedWork W2127696186 @default.
• W2058521000 hasRelatedWork W2146279127 @default.
• W2058521000 hasRelatedWork W2151687023 @default.
• W2058521000 hasRelatedWork W2311467655 @default.
• W2058521000 hasRelatedWork W2409239144 @default.
• W2058521000 hasRelatedWork W2417330922 @default.
• W2058521000 hasRelatedWork W2463126995 @default.
• W2058521000 hasRelatedWork W2528816819 @default.
• W2058521000 hasRelatedWork W2751537755 @default.
• W2058521000 hasRelatedWork W2766297112 @default.
• W2058521000 hasRelatedWork W3160932352 @default.
• W2058521000 hasRelatedWork W3181407872 @default.
• W2058521000 hasRelatedWork W2186878623 @default.
• W2058521000 isParatext "false" @default.
• W2058521000 isRetracted "false" @default.
• W2058521000 magId "2058521000" @default.
• W2058521000 workType "article" @default.